Aimmune Therapeutics Inc (NASDAQ:AIMT) insider Douglas T. Sheehy sold 3,523 shares of the company’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $36.52, for a total transaction of $128,659.96. Following the transaction, the insider now owns 32,500 shares of the company’s stock, valued at $1,186,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Aimmune Therapeutics Inc (NASDAQ:AIMT) traded up $0.28 during trading hours on Wednesday, reaching $33.28. 709,999 shares of the company were exchanged, compared to its average volume of 1,420,000. Aimmune Therapeutics Inc has a 1 year low of $15.97 and a 1 year high of $42.00. The stock has a market cap of $1,690.00 and a price-to-earnings ratio of -16.08.
Hedge funds and other institutional investors have recently modified their holdings of the business. Hamilton Lane Advisors LLC acquired a new position in shares of Aimmune Therapeutics during the 4th quarter worth $2,982,000. Virtus Fund Advisers LLC acquired a new position in shares of Aimmune Therapeutics during the 4th quarter worth $391,000. Point72 Asset Management L.P. raised its stake in shares of Aimmune Therapeutics by 10.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock worth $27,222,000 after buying an additional 101,855 shares during the last quarter. Carillon Tower Advisers Inc. acquired a new position in shares of Aimmune Therapeutics during the 4th quarter worth $58,838,000. Finally, New York State Common Retirement Fund raised its stake in Aimmune Therapeutics by 39.8% in the 2nd quarter. New York State Common Retirement Fund now owns 37,600 shares of the biotechnology company’s stock valued at $773,000 after purchasing an additional 10,699 shares during the last quarter. Institutional investors own 62.04% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://stocknewstimes.com/2018/03/14/aimmune-therapeutics-inc-aimt-insider-douglas-t-sheehy-sells-3523-shares.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.